We used the three years follow up (3Y-DFS, 3Y-OS) to determine possible differences: The 3Y-DFS in the MGMT promoter hypermethylated cohort is 81.1% and 3Y-OS = 88.6%, compared to the cohort with MGMT promoter unmethylated BC: 3Y-DFS = 78.4% and 3Y-OS is 88.6% (Fig 4). The gene discussed is MGMT; the disease is breast cancer.